



PDF



Full Text



Share



Viewpoint

June 5, 2018

Value-Based Pricing for Drugs Theme and Variations

Anna Kaltenboeck, MA¹; Peter B. Bach, MD²[» Author Affiliations](#)

JAMA. 2018;319(21):2165-2166. doi:10.1001/jama.2018.4871

In December 2017, the US Food and Drug Administration approved voretigene neparvovec-rzyl (Luxturna), a one-time genetic treatment manufactured by Spark Therapeutics that must be injected into the eye and can improve the vision of individuals with biallelic *RPE65* mutation-associated retinal dystrophy, a rare genetic condition that affects approximately 1000 to 2000 people in the United States each year. The therapy was priced \$850 000 per treatment, just below the million dollar threshold some had anticipated.



Full Text



Access through your institution

Read More About

Health Care Economics, Insurance, Payment

Pharmacoeconomics

**US Public Health
Preparedness and Response
to Highly Pathogenic Avian
Influenza A(H5N1) Viruses**

Read the study



Others Also Liked